BRCA2 and ovarian cancer: The enzymatic inhibition of DNA repair PARPs by small molecules has pioneered a synthetically lethal target therapy strategy for treatment of tumours characterised by DDR defects, such as breast and ovarian cancer carrying BRCA1 and BRCA2 mutations [7, 8].